H.C. Wainwright analyst Vernon Bernardino raised the firm’s price target on Humacyte (HUMA) to $15 from $12 and keeps a Buy rating on the shares after the FDA granted full approval for Symvess for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and when autologous vein graft is not feasible.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUMA:
- Humacyte announces FDA approval for Symvess
- Shareholder Alert for Humacyte, Inc. (NASDAQ:HUMA)
- Humacyte announces publication of results on ATEV
- HUMA LAWSUIT ALERT: Levi & Korsinsky LLP Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
- Spirit enters into bankruptcy proceedings, CVS names new directors: Morning Buzz